• Yi-Chieh Hung, Cheng-Chia Lee, Huai-Che Yang, Nasser Mohammed, Kathryn N Kearns, Ahmed M Nabeel, Khaled Abdel Karim, Reem M Emad Eldin, El-ShehabyAmr M NAMN6Gamma Knife Center Cairo, Nasser Institute Hospital, Cairo.Departments of16Neurosurgery and., Wael A Reda, Sameh R Tawadros, Roman Liscak, Jana Jezkova, L Dade Lunsford, Hideyuki Kano, Nathaniel D Sisterson, Martínez ÁlvarezRobertoR11Radiosurgery Unit, Hospital Ruber Internacional, Madrid, Spain., Nuria E Martínez Moreno, Douglas Kondziolka, John G Golfinos, Inga Grills, Andrew Thompson, Hamid Borghei-Razavi, Tanmoy Kumar Maiti, Gene H Barnett, James McInerney, Brad E Zacharia, Zhiyuan Xu, and Jason P Sheehan.
• 1Department of Neurological Surgery, University of Virginia, Charlottesville, Virginia.
• J. Neurosurg. 2020 Sep 1; 133 (3): 717726717-726.

ObjectiveThe most common functioning pituitary adenoma is prolactinoma. Patients with medically refractory or residual/recurrent tumors that are not amenable to resection can be treated with stereotactic radiosurgery (SRS). The aim of this multicenter study was to evaluate the role of SRS for treating prolactinomas.MethodsThis retrospective study included prolactinomas treated with SRS between 1997 and 2016 at ten institutions. Patients' clinical and treatment parameters were investigated. Patients were considered to be in endocrine remission when they had a normal level of prolactin (PRL) without requiring dopamine agonist medications. Endocrine control was defined as endocrine remission or a controlled PRL level ≤ 30 ng/ml with dopamine agonist therapy. Other outcomes were evaluated including new-onset hormone deficiency, tumor recurrence, and new neurological complications.ResultsThe study cohort comprised 289 patients. The endocrine remission rates were 28%, 41%, and 54% at 3, 5, and 8 years after SRS, respectively. Following SRS, 25% of patients (72/289) had new hormone deficiency. Sixty-three percent of the patients (127/201) with available data attained endocrine control. Three percent of patients (9/269) had a new visual complication after SRS. Five percent of the patients (13/285) were recorded as having tumor progression. A pretreatment PRL level ≤ 270 ng/ml was a predictor of endocrine remission (p = 0.005, adjusted HR 0.487). An increasing margin dose resulted in better endocrine control after SRS (p = 0.033, adjusted OR 1.087).ConclusionsIn patients with medically refractory prolactinomas or a residual/recurrent prolactinoma, SRS affords remarkable therapeutic effects in endocrine remission, endocrine control, and tumor control. New-onset hypopituitarism is the most common adverse event.

3 keywords...

hide…